By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CHEMICON International, Inc. 

28820 Single Oak Drive

Temecula  California  92590  U.S.A.
Phone: 909-676-8080-or-800-437-7500 Fax: 909-676-9209

CHEMICON is a leading supplier of research solutions via products and services for basic and biomedical research, drug discovery, and clinical diagnostics. We offer immunological reagents and kits, proteins, cell-based assays and molecular biology products to support researchers in the areas of neuroscience, stem cell biology, signal transduction, cancer, apoptosis, infectious disease, cytokines, CD markers, RNA interference, methylation, and more. We also offer products and services for drug discovery researchers, and a proprietary line of GPCR membrane preparations and cell lines offering superior value and performance, as well as a full line of services for custom cell line creation and custom assay design, to suit any discovery or screening needs. All of our research and discovery offerings are united by a commitment to custom services that can provide bulk or custom solutions to researchers’ specific needs.

As a part of Serologicals Corporation, Chemicon is partnered with the Upstate Group and Celliance, to provide an even wider array of solutions for the drug discovery, multiplexing and bioprocessing markets. Chemicon sells and markets its products and services directly in North America, Canada, Australia, and much of Europe, and throughout the rest of the world via a network of distributor partners.

SEROLOGICALS CORPORATION, headquartered in Atlanta, Georgia, is a global provider of biological products, enabling technologies and custom services to life science companies and research organizations. The Company’s diverse customer base includes major life science companies and leading research institutions. Our customers use our products, technologies and services in all facets of their activities, including basic research, drug discovery, development and bio-manufacturing. Our products, technologies and services are essential tools for research in a range of key disciplines, including oncology, hematology, immunology, cardiology, neurology, proteomics, infectious diseases, cell signaling and stem cell research.

In addition, the Company is the world’s leading manufacturer of monoclonal antibodies for the blood typing industry. Serologicals has more than 1000 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO.

Last Updated: 02-09-05

Key Statistics

Ownership: Subsidiary

Web Site: CHEMICON International, Inc.
Employees: 350
Symbol: SERO

Company News
ReNeuron And CHEMICON International, Inc. (SERO) Enter Into Agreement For Exclusive Sale And Marketing Of ReNcell Neural Stem Cell Lines 4/18/2006 1:41:48 PM
CHEMICON International, Inc. (SERO) And Cellumen, Inc. Announce An R & D Agreement To Commercialize A Systems Cell Biology Approach To Cytotoxicity Profiling In Drug Discovery 2/7/2006 12:41:12 PM
CHEMICON International, Inc. (SERO) And MorphoSys AG Enter Into Worldwide Licensing Agreement For Research Antibodies 1/10/2006 10:47:07 AM
CHEMICON International, Inc. (SERO) Enters Into License Agreement With RheoGene, Inc. 11/28/2005 1:19:36 PM
CHEMICON International, Inc. (SERO) Announces Agreement With Stem Cell Sciences Ltd.10/19/2005 5:13:18 PM
CHEMICON International, Inc. (SERO) Expands Its Exclusive Agreement For Patented Compounds And Methods For Embryonic Stem - ES - Cell Research10/19/2005 5:13:12 PM
CHEMICON International, Inc. (SERO) Licenses Its Patented Amplifluor Technology For Cancer Diagnostics To OncoMethylome Sciences S.A. 10/19/2005 5:13:10 PM
CHEMICON International, Inc. (SERO) Licenses Quantum Dot Antibody Reagent Line From Quantum Dot Corporation10/19/2005 5:12:56 PM
Sentigen Holding Corp. Announces The Sale Of Its Specialty Media Division To Serologicals Corporation's (SERO) CHEMICON International, Inc. (SERO)10/19/2005 5:12:48 PM
CHEMICON International, Inc. (SERO) Expands Stem Cell Franchise Through Acquisition Of Specialty Media10/19/2005 5:12:48 PM